Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms
Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.
Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.
SL-401 is a monoclonal antibody conjugate which targets a protein called CD-123, Patnaik explains. CD-123 is conjugated with a diphtheria toxin which increases its efficacy in killing malignant cells, Patnaik said.
The study was designed based on the success seen with CD-123 in a rate, but agressive, blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN).
<<<
